CLINICAL TRIALS AND OBSERVATIONS A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
نویسندگان
چکیده
1Institut Paoli-Calmettes, Marseille, France; 2Aix-Marseille Université, Marseille, France; 3Centre de Recherche en Cancérologie de Marseille, Marseille, France; 4Institut Gustave Roussy, Villejuif, France; 5Hopital Saint Louis, Paris, France; 6Centre Hospitalier Universitaire de Limoges, Limoges, France; 7Innate Pharma, Marseille, France; 8The Ohio State University and Comprehensive Cancer Center, Columbus, OH; and 9Infrastructures Biologie Sante et Agronomie Cancer Immunomonitoring Platform
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR ant...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic activity of epigenetic priming with decitabine before standard induction chemotherapy in patients with less-thanfavorable risk of acute myelogenous leukemia (AML). We directly compared the clinical and DNA-hypomethylating activity of decitabine delivered at 20 mg/m2 by either a 1-hour infusion (Arm A) or a ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR). Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subs...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies. We evaluated the efficacy of lenalidomide as frontline therapy for older AML patients. In this phase 2 study, patients 60 years of age or older with untreated AML received highdose (HD) lenalidomide at 50 mg daily for up to 2 28-day cycles. If pa...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse. We hypothesized that inhibition of the CXCR4/CXCL12 axis by the small molecule inhibitor, plerixafor, would disrupt the interaction of leukemic blasts with the environment and increase the sensitivity of AML blasts...
متن کامل